Chromocell Therapeutics Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
| December 31, | December 31, | |
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash | $96,391 | $55,074 |
| TOTAL CURRENT ASSETS | 96,391 | 55,074 |
| TOTAL ASSETS | $96,391 | $55,074 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $4,620,925 | $2,993,920 |
| Accrued compensation | 645,947 | 221,875 |
| Bridge loan, net of debt discount | 316,324 | 435,630 |
| Loan payable, net of debt discount | 202,279 | — |
| Loan payable - related party, net of debt discount | 750,082 | 104,800 |
| Due to Chromocell Corporation | 5,386 | 5,386 |
| TOTAL CURRENT LIABILITIES | 6,540,943 | 3,761,611 |
| TOTAL LIABILITIES | 6,540,943 | 3,761,611 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock Series A, $0.001 par value, 700,000 shares authorized, 600,000 and 600,000 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 60 | 60 |
| Preferred stock series B, $0.001 par value, 5,000 shares authorized, 0 and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Preferred stock series C, $0.001 par value, 5,000 shares authorized, 0 and 0 shares issued and outstanding as of December 31, 2023 and 2022, respectively | — | — |
| Common stock, $0.001 par value, 100,000,000 shares authorized, 3,914,338 and 1,111,112 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 391 | 111 |
| Additional paid in capital | 7,074,646 | 2,432,148 |
| Accumulated / parent’s net deficit | (13,519,649) | (6,138,856) |
| TOTAL STOCKHOLDERS’ DEFICIT | (6,444,552) | (3,706,537) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $96,391 | $55,074 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.